Wojcieszek Piotr, Białas Brygida
Brachytherapy Department, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Gliwice, Poland.
J Contemp Brachytherapy. 2012 Jun;4(2):116-20. doi: 10.5114/jcb.2012.29370. Epub 2012 Jun 30.
Prostate cancer, due to wide availability of PSA tests, is very often diagnosed in early stage, nowadays. This makes management of this disease even harder in every day oncology care. There is a wide range of treatment options including surgery, radiotherapy and active surveillance, but essential question is which treatment patient and oncologist should decide for. Due to recent publication of Prostate Cancer Results Study Group, in which brachytherapy is one of supreme curative options for prostate cancer, we decided to overview most present european and north american recommendations. National Comprehensive Cancer Network, American Society for Radiation Oncology, American Brachytherapy Society, European Association of Urology and Groupe Européen de Curiethérapie of European Society for Therapeutic Radiation Oncology guidelines are overviewed, particularly focusing on HDR and LDR brachytherapy.
由于前列腺特异性抗原(PSA)检测的广泛应用,如今前列腺癌常常在早期就被诊断出来。这使得在日常肿瘤护理中对这种疾病的管理变得更加困难。治疗选择范围广泛,包括手术、放疗和主动监测,但关键问题是患者和肿瘤学家应决定采用哪种治疗方法。鉴于前列腺癌结果研究小组最近发表的报告,其中近距离放射治疗是前列腺癌的最佳治愈选择之一,我们决定概述当前欧洲和北美的大多数建议。对美国国立综合癌症网络、美国放射肿瘤学会、美国近距离放射治疗学会、欧洲泌尿外科学会以及欧洲放射治疗与肿瘤学会欧洲近距离治疗小组的指南进行了概述,尤其侧重于高剂量率(HDR)和低剂量率(LDR)近距离放射治疗。